Cyclosporine 0.1% (Ikervis®) treatment in steroid-dependent dupilumab-associated conjunctivitis
Arch Soc Esp Oftalmol (Engl Ed). 2019 Aug;94(8):396-399.
doi: 10.1016/j.oftal.2019.04.013.
Epub 2019 Jun 6.
[Article in
English,
Spanish]
Affiliations
- 1 Departamento de Dermatología, Hospital Universitari i Politecnic La Fe, Valencia, España.
- 2 Departamento de Oftalmología, Hospital Universitari i Politecnic La Fe, Valencia, España. Electronic address: miriamrahhal@hotmail.com.
Abstract
Dupilumab is a drug that has recently been approved by the Food and Drug Administration (FDA) and European Medical Agency (EMA) for the treatment of moderate-to-severe atopic dermatitis in adults. An increase in frequency of conjunctivitis related to dupilumab treatment has been reported in recent publications and clinical trials. We report two steroid-dependent cases satisfactorily treated with cyclosporine 0.1% (Ikervis®). To our knowledge there are no reported cases of dupilumab-associated conjunctivitis treated with cyclosporine 0.1% (Ikervis®).
Keywords:
Atopic dermatitis; Ciclosporina; Conjunctivitis; Conjuntivitis; Cyclosporine; Dermatitis atópica; Dupilumab.
Copyright © 2019 Sociedad Española de Oftalmología. Publicado por Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Adrenal Cortex Hormones / therapeutic use
-
Adult
-
Antibodies, Monoclonal, Humanized / adverse effects*
-
Conjunctivitis / chemically induced*
-
Conjunctivitis / diagnostic imaging
-
Conjunctivitis / drug therapy*
-
Cyclosporine / therapeutic use*
-
Dermatitis, Atopic / drug therapy*
-
Female
-
Fluorometholone / therapeutic use
-
Glucocorticoids / therapeutic use
-
Humans
-
Immunosuppressive Agents / therapeutic use*
-
Interleukin-4 Receptor alpha Subunit
-
Male
-
Middle Aged
-
Recurrence
Substances
-
Adrenal Cortex Hormones
-
Antibodies, Monoclonal, Humanized
-
Glucocorticoids
-
Immunosuppressive Agents
-
Interleukin-4 Receptor alpha Subunit
-
dupilumab
-
Cyclosporine
-
Fluorometholone